Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed's interest ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...